Comparative Pharmacology
Head-to-head clinical analysis: ENFLONSIA versus ULTANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENFLONSIA versus ULTANE.
ENFLONSIA vs ULTANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENFLONSIA is a synthetic opioid that acts as a full agonist at mu-opioid receptors, producing analgesia, sedation, and euphoria. It also has weak activity at kappa and delta opioid receptors.
Sevoflurane is a volatile general anesthetic that enhances inhibitory neurotransmission via GABA-A and glycine receptors, and inhibits excitatory neurotransmission via NMDA and nicotinic acetylcholine receptors, producing anesthesia, amnesia, and muscle relaxation.
10 mg orally twice daily for 12 weeks; if tolerated and response inadequate, may increase to 20 mg twice daily.
Inhalation: Induction, 0.5-3% sevoflurane in oxygen or oxygen/nitrous oxide; maintenance, 1.5-3% sevoflurane with or without nitrous oxide.
None Documented
None Documented
Terminal half-life 12-16 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment.
Terminal elimination half-life of inorganic fluoride is approximately 2-5 hours (mean 3.0 h) in adults; context: prolonged with obesity or renal impairment.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal elimination as metabolites.
Renal excretion of inorganic fluoride metabolites accounts for >95% of elimination; <5% excreted unchanged in urine.
Category C
Category C
Inhalational Anesthetic
Inhalational Anesthetic